|
Vol 54(2020) N 2 p. 256-261; DOI 10.1134/S0026893320020119  T.D. Lebedev1, E.R. Vagapova1, O.O. Astashkova1, P.V. Spirin1, V.S. Prassolov1* Inhibition of Non-Receptor Tyrosine Kinase JAK2 Reduces Neuroblastoma Cell Growth and Enhances the Action of Doxorubicin 1Enhelgardt Institute of Molecular Biology Russian Аcademy of Science, Moscow, 119991 Russia*prassolov45@mail.ru Received - 2019-09-12; Revised - 2019-09-12; Accepted - 2019-09-19 Novel treatments for various types of malignant diseases are warranted. In this study, we evaluated JAK2 inhibitors (Janus kinase 2) for suppressing the growth of malignant neuroblastoma and glioblastoma cells as well as breast and non-small cell lung cancers. Neuroblastoma and glioblastoma cells are the most sensitive to the JAK2 inhibitor AG490. A study of the relative expression of receptors that can activate JAK2 suggests that cell line sensitivity to AG490 may be mediated by IL6-R, IL11-R and/or CSF1-R. AG490 enhances the effect of doxorubicin on neuroblastoma cells. Our findings suggest the possible relevance of JAK2 inhibitors for neuroblastoma therapy, especially in combination with doxorubicin. Janus kinase 2, JAK2, neuroblastoma, breast cancer, non-small cell lung cancer, glioblastoma, doxorubicin, combination therapy, malignant diseases |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
